- Home
- Find medicine
- Human medicines
- European public assessment reports
- Patient safety
- Pending EC decisions
- Withdrawn applications
- Paediatrics
- Rare disease designations
- Medicines under evaluation
- Medicines for use outside the EU
- Referrals
- Periodic safety update report single assessments
- Post-authorisation safety studies
- Shortages catalogue
- Recommendations on medication errors
- Veterinary medicines
- Herbal medicines for human use
- Human medicines
- Human regulatory
- Overview
- Research and development
- Adaptive pathways
- Advanced therapies
- Clinical trials
- Compassionate use
- Compliance
- Geriatric medicine
- Innovation in medicines
- Non-pharmaceutical products
- Orphan designation
- Paediatric medicines
- Pharmacovigilance
- PRIME: priority medicines
- Quality by design
- Scientific advice and protocol assistance
- Scientific guidelines
- Search guidelines
- Biologicals
- Clinical efficacy and safety
- Alimentary tract and metabolism
- Blood and blood-forming organs
- Blood products
- Cardiovascular system
- Dermatologicals
- Genitourinary system and sex hormones
- Anti-infectives for systemic use
- Antineoplastic and immunomodulating agents
- Rheumatology / musculoskeletal system
- Nervous system
- Respiratory system
- Radiopharmaceuticals and diagnostic agents
- Allergy/immunology
- Biostatistics
- General
- Clinical pharmacology and pharmacokinetics
- ICH
- Multidisciplinary
- Non-clinical
- Q&A on quality
- Quality
- Marketing authorisation
- Advanced therapies
- Accelerated assessment
- Biosimilars
- Compliance
- Clinical data publication
- Conditional marketing authorisation
- Generic medicines
- Guidance documents
- Orphan medicines
- Medicines for use outside EU (Article 58)
- Paediatric medicines
- Pharmacovigilance
- Pre-authorisation guidance
- Product information
- Submission dates
- Templates for assessors
- Post-authorisation
- Advanced therapies
- Compliance
- Data submission on medicines (Article 57)
- Medicine shortages
- Orphan medicines
- Improving quality of submissions
- Paediatric medicines
- Parallel distribution
- Pharmacovigilance
- European Risk Management Strategy
- Good pharmacovigilance practices
- Incident management plan
- Medical literature monitoring
- Medication errors
- Medicines under additional monitoring
- Periodic safety update reports
- Pharmacovigilance system
- Post-authorisation safety studies
- Regulatory and procedural guidance
- Signal management
- Post-authorisation procedural Q&A
- Regulatory and procedural guidance
- Templates for assessors
- Templates for industry
- Dossier submission requirements
- Classification of changes
- Pre-submission queries service
- Changing the name of a medicinal product
- Annual re-assessment
- Post-authorisation measures
- Renewals
- Annual renewal of conditional marketing authorisations
- PASS
- PAES
- Article 46 paediatric study submission
- Risk management plan (RMP)
- PSURs
- Transfer of marketing authorisations
- Transparency
- Article 61(3) Notifications
- Withdrawals and cessation
- Marketing and cessation notification
- Sunset clause monitoring
- Other
- Certificates for products
- Referral procedures
- Q&A: Urgent Union Procedures (Article 107i)
- Q&A: Article 13 referral procedures
- Q&A: Article 20 pharmacovigilance procedures
- Q&A: Article 20 non-pharmacovigilance procedures
- Q&A: Article 29(4) referral procedures
- Q&A: Article 30 referral procedures
- Q&A: Article 31 pharmacovigilance referrals
- Q&A: Article 31 non-pharmacovigilance referrals
- Guidance
- Variations
- Herbal products
- Veterinary regulatory
- Overview
- Research and development
- Marketing authorisation
- Post-authorisation
- Committees
- How the committees work
- CHMP
- CVMP
- PRAC
- COMP
- HMPC
- CAT
- PDCO
- Working parties and other groups
- CHMP
- Biologics Working Party
- Patients' and Consumers' Working Party
- Healthcare Professionals' Working Party
- Quality Working Party
- Safety Working Party
- Scientific Advice Working Party
- Biosimilar Medicinal Products Working Party
- Biostatistics Working Party
- Blood Products Working Party
- Cardiovascular Working Party
- Central Nervous System Working Party
- Excipients Drafting Group
- Gastroenterology Drafting Group
- Infectious Diseases Working Party
- Inter-Committee Scientific Advisory Group on Oncology
- (Invented) Name Review Group
- Oncology Working Party
- Pharmacogenomics Working Party
- Pharmacokinetics Working Party
- Radio-pharmaceuticals Drafting Group
- Respiratory Drafting Group
- Rheumatology / Immunology Working Party
- Vaccines Working Party
- Scientific Advisory Group on Cardiovascular Issues
- Scientific Advisory Group on Anti-infectives
- Scientific Advisory Group on Diabetes / Endocrinology
- Scientific Advisory Group on HIV/Viral Diseases
- Scientific Advisory Group on Neurology
- Scientific Advisory Group on Psychiatry
- Scientific Advisory Group on Vaccines
- Working Group on Quality Review of Documents
- Expert Group on 3Rs
- Active Substance Master File Working Group
- Geriatric Expert Group
- SmPC Advisory Group
- Modelling and Simulation Working Group
- CVMP
- Antimicrobials Working Party
- Efficacy Working Party
- Environmental Risk Assessment Working Party
- Immunologicals Working Party
- Quality Working Party
- Pharmacovigilance Working Party
- Safety Working Party
- Scientific Advice Working Party
- Inter-Committee Scientific Advisory Group on Oncology
- Ad Hoc Expert Group on Veterinary Novel Therapies
- Working Group on Quality Review of Documents
- Working Group on 3Rs
- Active Substance Master File Working Group
- COMP
- HMPC
- CAT
- PDCO
- CMDh
- CMDv
- EudraVigilance Expert Working Group
- CHMP
- News and Events
- Partners & Networks
- About Us
- What we do
- Who we are
- Management Board
- Executive Director
- Deputy Executive Director and support services
- Advisory functions
- Human Medicines Research and Development
- Human Medicines Evaluation
- Inspections, Human Medicines Pharmacovigilance and Committees
- Veterinary Medicines
- Stakeholders and Communication
- Information Management
- Administration and Corporate Management
- How we work
- European medicines regulatory network
- Information management
- Governance documents
- Annual reports and work programmes
- Funding
- Financial management and budgetary reporting
- Policies and procedures
- Integrated management system
- Legal foundation
- What we publish
- Access to documents
- Public hearings
- Transparency
- Competing interests
- Anti-fraud strategy
- Handling reports of alleged improprieties
- History of EMA
- Careers
- Procurement
- Support to research
- Contact
- Legal
- About this website
- FAQs
- Find medicine
CONTACT 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
Tel. +44 (0)20 3660 6000 Fax +44 (0)20 3660 5555 | LINKS | ASK EMA |
An agency of the European Union | ||
| |||||
RSS feed
Twitter
YouTube
